Dogwood Therapeutics, Inc (NASDAQ:DWTX) Short Interest Down 15.1% in February

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a significant decrease in short interest in the month of February. As of February 27th, there was short interest totaling 56,171 shares, a decrease of 15.1% from the February 12th total of 66,140 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average trading volume of 20,697 shares, the days-to-cover ratio is presently 2.7 days. Based on an average trading volume of 20,697 shares, the days-to-cover ratio is presently 2.7 days. Approximately 0.2% of the shares of the company are short sold.

Dogwood Therapeutics Price Performance

DWTX stock traded up $0.16 during midday trading on Tuesday, hitting $3.22. 34,486 shares of the stock traded hands, compared to its average volume of 47,599. Dogwood Therapeutics has a 1-year low of $2.60 and a 1-year high of $9.50. The stock’s fifty day simple moving average is $2.99 and its 200-day simple moving average is $4.71. The firm has a market cap of $103.30 million, a P/E ratio of -0.13 and a beta of 1.90.

Institutional Trading of Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new position in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned approximately 0.51% of Dogwood Therapeutics as of its most recent filing with the Securities and Exchange Commission. 9.05% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on DWTX shares. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Dogwood Therapeutics in a research report on Friday, February 20th. Wall Street Zen lowered Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.